Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. Seeks Balance On Drug Access In Trans Pacific Partnership IP Talks

This article was originally published in PharmAsia News

Executive Summary

The United States remains hopeful that a sharp debate on access and stricter intellectual property rules in the TPP talks can be concluded by the end of the year after talks in Indonesia failed to break an impasse.

You may also be interested in...



Free Trade Talks In Asia And Europe Impeded By Government Shutdown

As the shutdown continues, President Obama’s absence at negotiations on the Trans-Pacific Partnership could delay finalization of the free trade agreement. In addition, talks toward an EU-U.S. trade pact were canceled. Both agreements are expected to address device-specific trade issues.

Mixed Impact From Indonesian Foreign Ownership Changes?

A new economic stimulus package from the Indonesian government that includes allowing up to 100% foreign ownership in the pharmaceutical and health sectors has been welcomed by the multinational industry.

Indonesian Insurance Scheme ‘Not Sharia-Compliant’, Muslim Body Says

An edict by a top Muslim council in Indonesia that the country’s national health insurance does not follow Islamic sharia law principles has sparked debate in the world’s most populous Muslim-majority country.

Topics

Related Companies

UsernamePublicRestriction

Register

SC082681

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel